Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Liver Full Reference Set Application :Timothy Block - Drexel Univ (2010)

Liver Full Reference Set Application :Timothy Block - Drexel Univ (2010)

319
Feng, ZidingFred Hutchinson Cancer Research Center
GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers
Proteomics
G.I. and Other Associated Cancers Research Group
1

The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular carcinoma (HCC) in the background of liver cirrhosis. The use of the validation set would allow us to directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers

Directly compare GP73 and fucosylated markers against AFP, AFP-L3 and DCP as well as test them in combination with these markers
For data analysis, Receiver Operating Curves (ROC) should be generated for the Gp73 and fucosylated kininogen either alone and in combination with AFP, AFP-L3 and DCP and the area under the curve determined (AUROC). No training sets will be required. Markers will be directly compared by their AUROC values and ranked accordingly. The following will be criteria for advancement of a biomarker status and further testing: Statistically significant with alpha = 10% AUROC improvement in the distinction of cirrhosis from HCC with the addition of marker(s) to AFP alone for the full set of samples OR in defined subsets, e.g. AFP negatives, early tumor stage. The ultimate target is to find a combination of markers that will improve on current AFP-alone sensitivity and specificity, such that we will be able to achieve > 90% sensitivity and > 85% specificity for the distinction of cirrhosis from HCC.

No datasets are currently associated with this protocol.


Announcement 7/2/2018

The 33rd EDRN Steering Committee Meeting is from September 5-6, 2018 in Boston, MA. Please click here for meeting registration and hotel information.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.